ATRA-ATO Combination Therapy Improves Efficacy for Newly Diagnosed, High-Risk Acute Promyelocytic Leukemia Over Standard of Care
The chemotherapy-free combination of arsenic trioxide (ATO), all-trans retinoic acid (ATRA) plus low-dose idarubicin (ATRA-ATO) demonstrated a significantly higher two-year event-free survival ...
Ziftomenib Could Be Effective Option to Treat R/R NPM1-Mutated AML
KOMET-001 is a multicenter, open-label phase I/II trial of ziftomenib in adults with R/R AML. In the phase Ib/II portion of the trial, patients with NPM1-mutated AML received ...
FLAG-IDA Plus Venetoclax Performs Well in Children, AYA with Newly Diagnosed AML
The combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) plus venetoclax appeared to be a highly effective treatment regimen in ...
ASAP Trial Challenges Standard Practice of Remission Induction Before Transplant in AML
Despite widespread clinical adoption, the practice of inducing complete remission (CR) before allogeneic hematopoietic cell transplantation ...
Intermediate Dose of Cytarabine as Effective as Higher Dose for Post-Induction in AML
Thirty years ago, a seminal report by the Cancer and Leukemia Group established repeated courses of high-dose cytarabine (HDAC) as a good post-remission treatment option for patients with ...
p53 IHC Testing May Be Reliable Surrogate for Early Identification of TP53-Mutated MDS, AML
p53 immunohistochemistry (IHC) may be a useful and timely surrogate testing method for early characterization of TP53-mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia ...
Revumenib Looks to Fill a Therapeutic Void for Patients With R/R NPM1-Mutated AML
AUGMENT-101 was a phase I/II dose-escalation and expansion study testing revumenib in patients age 30 or older with R/R KMT2A-rearranged acute leukemia or NPM1-mutated AML ...
Menin Inhibitor Revumenib Yields Clinically Meaningful Responses in R/R NPM1-Mutated AML
Treatment with the menin inhibitor revumenib yielded “clinically meaningful” responses in patients with relapsed or refractory acute myeloid leukemia (R/R AML) with an NPM1 mutation ...
Phase II Results Point Toward a New Era in Treating Acute Myeloid Leukemia
Results from the phase II cohort of a trial evaluating the all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients with acute myeloid leukemia (AML) who are ...
Magrolimab Plus Azacitidine Did Not Improve Outcomes in TP53-Mutated AML
The combination of CD47-targeting magrolimab plus azacitidine did not improve survival compared with physician’s choice of treatment in patients with TP53-mutated acute myeloid leukemia ...
